Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparative trial of Masport vs commercial botulinum toxin for glabellar lines
IRCT2013100214871N1Phase 3Completed
- Sponsor
- Masoon Darou
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of abobotulinumtoxinA in glabellar furrowing (2 arms), sponsored by Masoon Darou. Started Jun 2014; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on IRCT2013100214871N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013100214871N1.